Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)

Trial Profile

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Doxorubicin (Primary) ; Lurbinectedin (Primary) ; Cyclophosphamide; Topotecan; Vincristine
  • Indications Bronchial cancer; Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLANTIS
  • Sponsors PharmaMar
  • Most Recent Events

    • 10 Oct 2017 According to a PharmaMar media release, trial will be presented at the IASCLC 18th World Lung Conference in Yokohama, Japan.
    • 31 Aug 2017 According to a PharmaMar media release, completion of enrollment is expected around first half of 2018.
    • 02 Aug 2016 According to a PharmaMar media release, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top